Are we entering a new frontline era for HER2-positive gastroesophageal cancer?

This episode of the PeerDirect Medical News Podcast reviews emerging ASCO 2026 and NEJM data that could reshape frontline oncology care, including zanidatamab-based therapy in HER2-positive gastroesophageal adenocarcinoma, earlier-line teclistamab in relapsed/refractory multiple myeloma, and updated NRG-GY018 findings supporting pembrolizumab plus chemotherapy in advanced endometrial cancer. The discussion highlights evolving roles for bispecific antibodies, chemo-immunotherapy, and HER2-targeted strategies across solid tumors and hematologic malignancies.